Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...

SAN DIEGO — Novartis, a Swiss pharmaceutical company, announced a planned $23 billion investment over the next five years aimed at expanding its U.S.-based infrastructure. The move ensures that ...